Real-life assessment of Volumetric Modulated Arc Therapy (VMAT) toxicity in Head and Neck Squamous Cell Carcinoma (HNSCC) treatment

References

• Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890–9.
   PubMed Web of Science ®Google Scholar
• Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. PARSPORT trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011;12:127–36.
   PubMed Web of Science ®Google Scholar
• Scorsetti M, Fogliata A, Castiglioni S, Bressi C, Bignardi M, Navarria P, et al. Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients. Radiat Oncol 2010;5:93. doi:10.1186/1748-717X-5-93.
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–4.
   PubMed Web of Science ®Google Scholar
• Lapeyre M, Henrot P, Alfonsi M, Bardet E, Bensadoun RJ, Dolivet G, et al. Groupe Oncologie Radiothérapie Tête et Cou. Propositions for the selection and the delineation of peritumoral microscopic disease volumes in oral cavity and oropharyngeal cancers (lymph nodes excluded). Cancer Radiother 2005;9:261–70.
   PubMedGoogle Scholar
• Lapeyre M, Bailly C, Toledano I, Montalban A, Russier M. Hypopharynx and larynx cancers: propositions for the selection and the delineation of peritumoral microscopic disease volumes (lymph nodes excluded). Cancer Radiother 2010;14(Suppl 1):S43–51.
   PubMedGoogle Scholar
• Grégoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol 2006;79:15–20.
   PubMed Web of Science ®Google Scholar
• Chao KS, Wippold FJ, Ozyigit G, Tran BN, Dempsey JF. Determination and delineation of nodal target volumes for head-and-neck cancer based on patterns of failure in patients receiving definitive and postoperative IMRT. Int J Radiat Oncol Biol Phys 2002;53:1174–84.
   PubMed Web of Science ®Google Scholar
• Chao KS, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2003;55:312–21.
   PubMed Web of Science ®Google Scholar
• Tsan DL, Lin CY, Kang CJ, Huang SF, Fan KH, Liao CT, et al. The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol 2012;7:215. doi:10.1186/1748-717X-7-215.
   PubMed Web of Science ®Google Scholar
• Jeremic B, Milicic B, Dagovic A, Vaskovic Z, Tadic L. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2004;22:3540–8.
   PubMed Web of Science ®Google Scholar
• Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92–8.
   PubMed Web of Science ®Google Scholar
• Alongi F, Bignardi M, Garassino I, Pentimalli S, Cavina R, Mancosu P, et al. Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients. Strahlenther Onkol 2012;188:49–55.
   PubMed Web of Science ®Google Scholar
• Studer G, Brown M, Salgueiro EB, Schmückle H, Romancuk N, Winkler G, et al. Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT. Int J Radiat Oncol Biol Phys 2011;81:110–17.
   PubMed Web of Science ®Google Scholar
• Levy A, Blanchard P, Bellefqih S, Brahimi N, Guigay J, Janot F, et al. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. Strahlenther Onkol 2014;190:823–31.
   PubMed Web of Science ®Google Scholar
• Peponi E, Glanzmann C, Willi B, Huber G, Studer G. Dysphagia in head and neck cancer patients following intensity modulated radiotherapy (IMRT). Radiat Oncol 2011;6:1. doi:10.1186/1748-717X-6-1.
   PubMed Web of Science ®Google Scholar
• Studer G, Huguenin PU, Davis JB, Kunz G, Lütolf UM, Glanzmann C. IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients. Radiat Oncol 2006;1:7. doi:10.1186/1748-717X-1-7.
   PubMed Web of Science ®Google Scholar
• Toledano I, Graff P, Serre A, Boisselier P, Bensadoun RJ, Ortholan C, et al. Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004-03. Radiother Oncol 2012;103:57–62.
   PubMed Web of Science ®Google Scholar
• Setton J, Caria N, Romanyshyn J, Koutcher L, Wolden SL, Zelefsky MJ, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2012;82:291–8.
   PubMed Web of Science ®Google Scholar
• Van Gestel D, Van Den Weyngaert D, Schrijvers D, Weyler J, Vermorken JB. Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience. Br J Radiol 2011;84:367–74.
   PubMed Web of Science ®Google Scholar